Patents Assigned to Merck
  • Anti-TIGIT antibodies
    Patent number: 10766957
    Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: September 8, 2020
    Assignee: MERCK SHARP & DOHME CORP
    Inventors: Sybil M. G. Williams, Wolfgang Seghezzi, Laurence Fayadat-Dilman, Linda Liang, Veronica Juan
  • Cyclic di-nucleotide compounds as sting agonists
    Patent number: 10766919
    Abstract: A class of polycyclic compounds of general formula (I), of general formula (I?), or of general formula (I?), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: September 8, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brian Andresen, Wonsuk Chang, Matthew Lloyd Childers, Jared N. Cumming, Andrew Marc Haidle, Timothy J. Henderson, James P. Jewell, Rui Liang, Jongwon Lim, Hong Liu, Min Lu, Alan B. Northrup, Ryan D. Otte, Tony Siu, Benjamin Wesley Trotter, Quang T. Truong, Shawn P. Walsh, Kake Zhao
  • Auto-injector for epinephrine injection
    Patent number: 10765809
    Abstract: A reloadable auto injector has a needle insertion driver to be re-activated upon reloading. A syringe is movably positioned in a housing between a first position and a second position. A plunger rod is locked to a plunger rod tube by a deflectable locking member. A syringe driver applies a force to the syringe to move the syringe together with plunger rod tube, plunger rod and plunger rod driver from the first position to the second position. In the second position, the locking member is unlocked and releases the plunger rod to thereby activate the plunger rod driver to advance the plunger rod in the syringe for delivering of medicament. A reload handle is connected to the syringe assembly so that user operation of the reload handle retracts the syringe to the first position and simultaneously reloads the syringe driver for delivering a further dose of medicament.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: September 8, 2020
    Assignee: MERCK PATENT GMBH
    Inventors: Soeren Bechmann, Flemming Madsen, Esben Johansen
  • Aminopyrazoles as janus kinase inhibitors
    Patent number: 10766883
    Abstract: The instant invention provides compounds which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: September 8, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Peter Fuller, Jason Brubaker, Hongbo Zeng, Joshua Close, Jonathan Young
  • NOVEL SUBSTITUTED CYCLOBUTYLBENZENE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS
    Publication number: 20200277252
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: October 4, 2018
    Publication date: September 3, 2020
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Meredeth Ann McGowan, Abdelghani Achab, Xavier Fradera, Yongxin Han, Derun Li, Jongwon Lim, Kun Liu, Nunzio Sciammetta, Catherine M. White, Wensheng Yu, Hongjun Zhang, Hua Zhou
  • PHARMACEUTICAL COMPOSITIONS OF A PEPTIDE
    Publication number: 20200276274
    Abstract: Disclosed are pharmaceutical compositions comprising the peptide of SEQ ID No. 1, or a pharmaceutically acceptable salt or counterion thereof, methods of preparing such pharmaceutical compositions, and methods of treating diabetes and diabetes-related disorders with such pharmaceutical compositions.
    Type: Application
    Filed: February 26, 2020
    Publication date: September 3, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Himanshu Bhattacharjee, Suzanne M. D'Addio, Sachin Lohani, Sachin Mittal, Sergei Y. Pechenov, Daniel Hong Yin
  • MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES
    Publication number: 20200277284
    Abstract: The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
    Type: Application
    Filed: October 15, 2018
    Publication date: September 3, 2020
    Applicant: Merck Patent GmbH
    Inventors: Rouven Linge, Sebastian Meyer, Lara-Isabel Rodriguez
  • METHOD FOR PRODUCING FLUORINATED COMPOUNDS
    Publication number: 20200277247
    Abstract: The present invention relates to a process for the preparation of fluorinated compounds, to novel compounds containing fluorinated end groups, to the use thereof and to compositions comprising novel compounds containing fluorinated end groups.
    Type: Application
    Filed: September 24, 2018
    Publication date: September 3, 2020
    Applicant: MERCK PATENT GMBH
    Inventors: Reiner FRIEDRICH, Fabian KOCH
  • PROCESSES FOR THE FORMULATION OF PNEUMOCOCCAL POLYSACCHARIDES FOR CONJUGATION TO A CARRIER PROTEIN
    Publication number: 20200276316
    Abstract: The present invention provides a number of process improvements related to the conjugation of capsular polysaccharides from Streptococcus pneumoniae to a carrier protein. These process are serotype specific and include acid hydrolysis, addition of sodium chloride to the reductive amination reaction, and addition of sucrose to dissolve polysaccharides. Polysaccharide-protein conjugates prepared using the processes of the invention can be included in multivalent pneumococcal conjugate vaccines.
    Type: Application
    Filed: September 4, 2018
    Publication date: September 3, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Patrick McHugh, Michael Albert Winters, Janelle Konietzko
  • COMPOSITIONS AND METHODS FOR TREATING CANCER WITH A COMBINATION OF PROGRAMMED DEATH RECEPTOR (PD-1) ANTIBODIES AND A CXCR2 ANTAGONIST
    Publication number: 20200276153
    Abstract: The present invention relates to methods of treating a cell proliferation disorder (e.g., cancer) comprising administering: (a) a compound having the Formula (I), wherein R1 or R2 are as herein defined, or a pharmaceutically acceptable salt thereof; and (b) an anti-human PD-1 antibody or antigen binding fragment thereof to a human patient in need thereof. Also disclosed are therapeutic combinations and kits containing such agents for the treatment of cancers.
    Type: Application
    Filed: September 24, 2018
    Publication date: September 3, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Elaine M Pinheiro, Michael Rosenzweig, Robert A. Kastelein, David R. Kaufman, Deborah A. Law
  • CYSTEINE ENGINEERED ANTIGEN-BINDING MOLECULES
    Publication number: 20200277399
    Abstract: A specific antigen-binding member (ABM) comprising a specific antigen-binding moiety and an antibody Fc region comprising a CH2 domain, which is engineered for a cysteine substitution at position 108 and/or 113, wherein numbering is according to the IMGT, and wherein the antibody Fc region does not comprise an antigen-binding CH3 domain; and an ABM conjugate (ABMC) comprising the ABM and at least one heterologous molecule covalently conjugated to one or both of the cysteines at positions 108 and 113 of the CH2 domain.
    Type: Application
    Filed: October 3, 2018
    Publication date: September 3, 2020
    Applicant: MERCK PATENT GMBH
    Inventors: Gordana WOZNIAK-KNOPP, Florian RÜKER, Gerhard STADLMAYR, Jakub RYBKA, Nicolas RASCHE, Stephan DICKGIESSER
  • METHOD FOR THE PRODUCTION OF SYNTHETIC LEATHER
    Publication number: 20200277731
    Abstract: The present invention relates to a method for the production of synthetic leather, to synthetic leather produced by such a method as well as to the use thereof. In particular, the present invention relates to a method for the production of synthetic leather exhibiting a virtual three-dimensional pattern on its visible face, whereby the leather comprises platelet-shaped effect pigments.
    Type: Application
    Filed: November 12, 2018
    Publication date: September 3, 2020
    Applicant: Merck Patent GmbH
    Inventor: Edric CHEN
  • Organic semiconducting compounds
    Patent number: 10759775
    Abstract: The invention relates to novel organic semiconducting compounds containing a polycyclic unit, to methods for their preparation and educts or intermediates used therein, to compositions, polymer blends and formulations containing them, to the use of the compounds, compositions and polymer blends as organic semiconductors in, or for the preparation of, organic electronic (OE) devices, especially organic photovoltaic (OPV) devices, organic photodetectors (OPD), organic field effect transistors (OFET) and organic light emitting diodes (OLED), and to OE, OPV, OPD, OFET and OLED devices comprising these compounds, compositions or polymer blends.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: September 1, 2020
    Assignee: MERCK PATENT GmbH
    Inventors: Graham Morse, Lana Nanson, William Mitchell, Michal Krompiec, Mansoor D'Lavari, Agnieszka Pron
  • Anti-PD-L1 antibodies and uses thereof
    Patent number: 10759856
    Abstract: The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: September 1, 2020
    Assignee: Merck Patent GmbH
    Inventors: Horacio G. Nastri, Christel Iffland, Olivier Leger, Qi An, Mark Cartwright, Sean D. McKenna, Vanita D. Sood, Gang Hao
  • Cyclic di-nucleotide compounds as STING agonists
    Patent number: 10759825
    Abstract: A class of polycyclic compounds of general formula (I), of general formula (I?), or of general formula (I?), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: September 1, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brian Andresen, Wonsuk Chang, Matthew Lloyd Childers, Jared N. Cumming, James P. Jewell, Jongwon Lim, Alan B. Northrup, Ryan D. Otte, Benjamin Wesley Trotter, Quang T. Truong, Shawn P. Walsh, Kake Zhao
  • Liquid-crystal medium
    Patent number: 10759996
    Abstract: The present invention relates to a liquid crystal (LC) medium comprising polymerisable compounds, to a process for its preparation, to its use for optical, electro-optical and electronic purposes, in particular in LC displays, and to LC displays comprising it.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: September 1, 2020
    Assignee: MERCK PATENT GMBH
    Inventors: Mathias Bremer, Patrick Suess, Nils Greinert, Melanie Klasen-Memmer, Christian Schoenefeld
  • Compounds that are ERK inhibitors
    Patent number: 10759805
    Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (I).
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: September 1, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jongwon Lim, Xianhai Huang, Ronald D. Ferguson, Wei Zhou, Christopher W. Boyce, Phieng Siliphaivanh, David J. Witter, Milana M. Maletic, Joseph A. Kozlowski, Kevin J. Wilson
  • VARIABLE, MULTI-DOSE MICROTABLET DISPENSER
    Publication number: 20200268612
    Abstract: A microtablet dispenser is provided herein including: a microtablet reservoir disc including a plurality of wells each formed to accommodate at least one microtablet, the wells being arranged in at least one array; a screen plate having at least one opening shaped to expose all of the wells of one of the arrays when aligned therewith; and, a dose selector plate including a plurality of dosing apertures arranged in a plurality of dosing arrays of different patterns. With one of the arrays being aligned with the at least one opening of the screen plate and with a selected dosing array, the microtablets accommodated in the wells aligned with dosing apertures are free to pass through the corresponding dosing apertures so as to be dispensed therefrom, while the wells of the array not aligned with dosing apertures are obstructed by solid portions of the dose selector plate.
    Type: Application
    Filed: February 5, 2020
    Publication date: August 27, 2020
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Annaniy Berenshteyn, Mikhail Gotliboym, Christopher Granelli
  • ANTI-COAGULATION FACTOR XI ANTIBODIES
    Publication number: 20200270364
    Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
    Type: Application
    Filed: May 1, 2020
    Publication date: August 27, 2020
    Applicants: Merck Sharp & Dohme Corp., Adimab, LLC
    Inventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Vaishnavi Ganti, Mohammad Tabrizifard, Bianka Prinz
  • LONG-ACTING CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS
    Publication number: 20200270325
    Abstract: Long-acting co-agonists of the glucagon and GLP-1 receptors are described.
    Type: Application
    Filed: September 21, 2018
    Publication date: August 27, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Anandan Palani, Qiaolin Deng, Chunhui Huang, Yuping Zhu, Elisabetta Bianchi, Federica Orvieto